Company Active LTD

Company profile

Neobe Therapeutics Ltd

Error

Neobe Therapeutics Ltd is a UK company with status active founded in 2021 based in East of England.

CRN
13146056
Founded
2021
Age
5

Overview

Legal name
NEOBE THERAPEUTICS LTD
Region
East of England
Registered address
SALISBURY HOUSE
STATION ROAD
CAMBRIDGE
UNITED KINGDOM
CB1 2LA
Insolvency history
No

Latest accounts

Financial period: 1 Feb 2024 to 31 Dec 2024

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
6

Company events

Reference milestones and recent Companies House filing stream events.

7 events
30 Sep
2027

Accounts due

Accounts Due

Next accounts due date

03 Feb
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

20 Jan
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2025

Accounts filed

Accounts

Last accounts made up date

22 Oct
2024

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQ0MDQzOTEzMGFkaXF6a2N4

Published 22 Oct 2024 07:05

22 Oct
2024

Change Account Reference Date Company Current Shortened

Accounts Analysed

AA01 | Transaction MzQ0MDQ5OTQ1M2FkaXF6a2N4

Published 22 Oct 2024 02:51

20 Jan
2021

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2022
Funded years
2022, 2023, 2024
Age at first award
1 years

Projects

2024 Collaborative R&D Lead participant

Development and validation of a tumour inducible promoter platform for engineered live biotherapeutics

1 May 2024 to 31 Jan 2026

Awarded
£304,726
Total cost £435,323

Neobe Therapeutics is an early-stage start up developing a synthetic biology platform to enable immunotherapy success in currently non responding cancer patients. Our platform is based on safe strains of tumour colonizing bacteria, which are engineered to be activated within solid tumours to release payloads that remove local barriers to immune infiltrati...

2023 Collaborative R&D Lead participant

Pre-clinical development of a live biotherapeutic product engineered to remodel hyaluronic acid in solid tumours to enable checkpoint inhibitor efficacy

1 Dec 2023 to 30 Nov 2025

Awarded
£699,917
Total cost £999,881

Neobe Therapeutics is an early-stage start up developing a synthetic biology platform to enable immunotherapy success in currently non responding cancer patients. Our platform is based on safe strains of tumour colonizing bacteria, which are engineered to be activated within solid tumours to release payloads which remove local barriers to immune infiltrat...

2022 Collaborative R&D Lead participant

Engineering a new versican remodeling recombinant bacterial product to enable immunotherapy success in triple negative breast cancer

1 May 2022 to 30 Apr 2024

Awarded
£262,808
Total cost £375,440

The cancer therapeutics field has been revolutionized by immunotherapy. The development of drugs that recruit the immune system to recognize and eliminate cancer cells has led to an extraordinary increase in patient survival, in some tumour types. However, only around 20% of patients with solid tumours are estimated to currently benefit from them. Multipl...

Product types

Collaborative R&D